Drug Therapy for Heart Valve Diseases.

about

Fibrotic Aortic Valve Stenosis in Hypercholesterolemic/Hypertensive Mice.Serotonin and catecholamines in the development and progression of heart valve diseases.Impact of Beta-Blockade on Cardiac Events in Patients with Chronic Severe Nonischemic Mitral Regurgitation.

P2860

Q36619540-755BBD21-F21C-4488-8AC3-E3C3030F6EFD Q38634250-1A5EF740-BC4F-43F2-B86F-F4F4959E67A0 Q47775576-E566B9BC-5B03-4467-9B43-F755A4382CC7

P2860

Drug Therapy for Heart Valve Diseases.

Item

http://www.wikidata.org/entity/Q36091454

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Drug Therapy for Heart Valve Diseases.

@ast

Drug Therapy for Heart Valve Diseases.

@en

type

Item

label

Drug Therapy for Heart Valve Diseases.

@ast

Drug Therapy for Heart Valve Diseases.

@en

prefLabel

Drug Therapy for Heart Valve Diseases.

@ast

Drug Therapy for Heart Valve Diseases.

@en

P1476

Drug Therapy for Heart Valve Diseases.

@en

P2093

Abhishek Sharma

http://www.w3.org/2001/XMLSchema#string

Jeffrey S Borer

http://www.w3.org/2001/XMLSchema#string

P2860

Bone morphogenic protein 2 induces Runx2 and osteopontin expression in human aortic valve interstitial cells: role of Smad1 and extracellular signal-regulated kinase 1/2

Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis

Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study

Long-term nifedipine unloading therapy in asymptomatic patients with chronic severe aortic regurgitation

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility

Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis

Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS).

The natural history of 271 patients with mitral stenosis under medical treatment

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

P304

1038-1045

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.115.016006

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

132

http://www.w3.org/2001/XMLSchema#string

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26371236

http://www.w3.org/2001/XMLSchema#string

P932

4582425

http://www.w3.org/2001/XMLSchema#string

Drug Therapy for Heart Valve Diseases.

about

P2860

P2860

Drug Therapy for Heart Valve Diseases.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932